Lijnen H R, Silence J, Lemmens G, Frederix L, Collen D
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Thromb Haemost. 1998 Jun;79(6):1171-6.
To investigate a potential physiological role of the plasminogen/plasmin system in activation of the matrix metalloproteinase (MMP) system, the distribution of latent and active MMP-2 (gelatinase A) or MMP-9 (gelatinase B) was monitored in aorta extracts and in serum-free conditioned cell culture medium obtained from wild-type (WT) mice and from mice with deficiency of tissue-type plasminogen activator (t-PA(-/-)), urokinase-type plasminogen activator (u-PA(-/-)), plasminogen activator inhibitor-1 (PAI-1(-/-)) or plasminogen (Plg(-/-)). In aorta extracts, the contribution of active MMP-2 to the total MMP-2 level ranged between 7 and 16% for the different genotypes, whereas active MMP-9 was not detected. The contribution of active 58 kDa MMP-2 to the total MMP-2 level (active plus latent) ranged between 14 and 29% (mean of 3 experiments) for fibroblasts of the different genotypes, and between 18 and 32% for smooth muscle cells, and was relatively constant in time (7-72 h). The contribution of active 83 kDa MMP-9 to the total MMP-9 level ranged between 15 and 29% for fibroblasts of the different genotypes and was relatively constant in time (24-72 h); corresponding values were 17 to 57% for smooth muscle cells, with the exception of Plg(-/-) smooth muscle cells which had undetectable levels of active MMP-9. Addition of plasmin(ogen) to the cell culture medium of fibroblasts did not significantly affect the distribution of active and latent MMP-2, but resulted in an approximately two-fold enhancement of the contribution of active MMP-9. In macrophages of Plg(-/-) mice, active MMP-9 was detected only when the cells were cultured in the presence of plasminogen. These data indicate that activation of proMMP-2 occurs independently of the physiological plasminogen activators and of plasmin(ogen) in all the cell types evaluated. Activation of proMMP-9 was enhanced in the presence of plasmin(ogen), but active MMP-9 was also detected in fibroblasts of Plg(-/-) mice, indicating that in vivo activation may occur via plasmin(ogen)-independent mechanisms.
为研究纤溶酶原/纤溶酶系统在基质金属蛋白酶(MMP)系统激活过程中的潜在生理作用,我们监测了野生型(WT)小鼠以及组织型纤溶酶原激活物缺陷(t-PA(-/-))、尿激酶型纤溶酶原激活物缺陷(u-PA(-/-))、纤溶酶原激活物抑制剂-1缺陷(PAI-1(-/-))或纤溶酶原缺陷(Plg(-/-))小鼠的主动脉提取物和无血清条件细胞培养基中潜伏型和活性型MMP-2(明胶酶A)或MMP-9(明胶酶B)的分布情况。在主动脉提取物中,不同基因型小鼠活性MMP-2占总MMP-2水平的比例在7%至16%之间,而未检测到活性MMP-9。不同基因型成纤维细胞中,活性58 kDa MMP-2占总MMP-2水平(活性型加潜伏型)的比例在14%至29%之间(3次实验的平均值),平滑肌细胞中该比例在18%至32%之间,且在7至72小时内相对稳定。不同基因型成纤维细胞中,活性83 kDa MMP-9占总MMP-9水平的比例在15%至29%之间,且在24至72小时内相对稳定;平滑肌细胞的相应比例为17%至57%,但Plg(-/-)平滑肌细胞中活性MMP-9水平未检测到。向成纤维细胞的细胞培养基中添加纤溶酶(原),对活性型和潜伏型MMP-2的分布没有显著影响,但导致活性MMP-9的贡献增加了约两倍。在Plg(-/-)小鼠的巨噬细胞中,只有当细胞在纤溶酶原存在的情况下培养时才能检测到活性MMP-9。这些数据表明,在所有评估的细胞类型中,proMMP-2的激活独立于生理性纤溶酶原激活物和纤溶酶(原)。在纤溶酶(原)存在的情况下,proMMP-9的激活增强,但在Plg(-/-)小鼠的成纤维细胞中也检测到了活性MMP-9,这表明体内激活可能通过纤溶酶(原)非依赖机制发生。